• Markets
    • icon
  • Companies
AGN · ASX

Argenica Therapeutics Ltd (ASX:AGN)

AU$0.5

 0.0 (0.0%)
ASX:Live
08/12/2023 03:56:40 PM
Hammer Bullish HALO Price Momentum HALO Ords HALO MQV HALO Momentum +8
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

AGN Overview

AGN Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About AGN

Website

N/A

Telephone

N/A

Address

Description

Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.

AGN Price Chart

Key Stats

Market Cap

AU$49.08M

PE

9.30

EV/EBITDA

1.0

Dividends Overview

DIV Yield

1.6%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.29 - 0.59

Trade Value (12mth)

AU$6,501.00

1 week

11.11%

1 month

49.25%

YTD

16.28%

1 year

-1.96%

All time high

1.02

Key Fundamentals

EPS 3 yr Growth

957.700%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-41.30%

ROIC

-60.30%

Interest Coverage

N/A

Quick Ratio

5.10

Other Data

Shares on Issue (Fully Dilluted)

88m

HALO Sector

Healthcare

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AGN Announcements

Latest Announcements

Date Announcements

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 May 23

Trading Halt

×

Trading Halt

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 December 21

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

30 November 23

Appointment of Non-Executive Chair

×

Appointment of Non-Executive Chair

30 November 22

Notification regarding unquoted securities - AGN

×

Notification regarding unquoted securities - AGN

30 November 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

30 March 23

Significant Non-Dilutive Funding For Preclinical HIE Studies

×

Significant Non-Dilutive Funding For Preclinical HIE Studies

30 March 22

Positive Preclincal Data on Efficacy in New Indication

×

Positive Preclincal Data on Efficacy in New Indication

29 September 23

Date of AGM & Closing Date For Director Nominations

×

Date of AGM & Closing Date For Director Nominations

29 September 22

Further Positive Preclinical Results for ARG-007 In HIE

×

Further Positive Preclinical Results for ARG-007 In HIE

29 July 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 February 23

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

28 February 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

27 October 23

Board Update

×

Board Update

27 October 21

Investor Presentation

×

Investor Presentation

27 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

27 August 21

Appendix 4E & Annual Report 30 June 2021

×

Appendix 4E & Annual Report 30 June 2021

27 April 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

26 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

26 October 22

No Serious Safety Issues Observed in First Cohort

×

No Serious Safety Issues Observed in First Cohort

26 April 22

Maximum Tolerated Dose Successfully Established in Studies

×

Maximum Tolerated Dose Successfully Established in Studies

25 October 23

Investor Presentation

×

Investor Presentation

25 November 22

Results of Annual General Meeting

×

Results of Annual General Meeting

25 November 22

AGM Presentation

×

AGM Presentation

25 November 22

Phase 1 Clinical Trial Progress Update

×

Phase 1 Clinical Trial Progress Update

AGN Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.06 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.06 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -171.2 -292.2 0.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 9.3 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 1.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.05 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -98.6 -305.3 -5.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -7.2 -10.6 -10.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 1.6 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.10 0.08 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.09 0.10 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39,250.2 2.1 -18.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 73 74 88 Lock Lock Lock
Basic m Lock Lock Lock Lock 73 74 88 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 1 4 7 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -1 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -245.5 -228.2 -52.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -1 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -245.5 -228.2 -52.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -4 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -4 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -168.5 -297.4 -17.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -3 -3 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 5 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1,679.0 -221.3 1.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 9 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 9 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -9 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 7 8 8 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 7 8 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37,116.6 21.3 -7.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -14.2 -45.2 -50.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -38.6 -57.4 -82.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -30.0 -54.0 -60.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.5 -44.4 -41.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -66,285.0 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 5.4 2.0 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -104.3 -107.3 -121.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.1 12.3 5.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.1 12.3 5.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 98.6 97.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -245.8 -456.8 -176.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -14.2 -45.2 -50.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

1.6%

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AGN Shortsell

Frequently Asked Questions

The current share price of Argenica Therapeutics Ltd (AGN:ASX) is AU$0.5.
The 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX) is AU$0.59.
The 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)? is AU$0.29.
The current TTM dividend payout for Argenica Therapeutics Ltd (AGN:ASX) is 1.60.
Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.
Argenica Therapeutics Ltd (AGN:ASX) has a franking level of 0%.
Argenica Therapeutics Ltd (AGN:ASX) is classified in the Healthcare.
The current P/E ratio for Argenica Therapeutics Ltd (AGN:ASX) is 9.30.
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.